Cardiac and vascular diseases continue to be the most common cause of death in the western world. Globally, more than 700.000 patients undergo coronary artery bypass surgery annually while about 600.000 patients have vascular surgery procedures performed. Medistim’s mission over the past three decades has been to serve patients, surgeons and health care providers with innovative and cost effective medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the quality and outcome of cardiac and vascular surgery.
One million beating hearts later, we have set the standard in the field.
Today, Medistim’s proprietary products are regarded to be standard-of-care in most European countries and Japan, while market adoption is growing in the USA, Asia and the Middle East. In addition, Medistim in Norway represents about 100 different medical technology companies, as a distributor of their products in this country.
Being an innovator and market leader within intra-operative transit time flow measurement (TTFM) and ultrasound imaging, Medistim is serving the global market with the devices VeriQ™, VeriQ C™ and the latest generation, MiraQ™. These systems enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. They provide clinically relevant information that empowers surgeons to make better-informed decisions in the operating room.
Our devices are developed by working closely together with surgeons, who in turn have produced a growing amount of clinical data and studies that point to their efficacy and cost-effectiveness. Medistim is committed to continuing to serve the cardiac and vascular surgeons by investing in new product development.
Medistim has wholly owned subsidiaries with marketing and sales organizations in the USA, Germany, the United Kingdom, Denmark and Norway, in addition to a global distributor network representing the company in more than 50 countries in Asia, Europe, America and Africa. Sales revenues reached MNOK 215 in 2014, with profit before tax of MNOK 45. Medistim ASA is listed on the Oslo Stock Exchange and has its global head office in Oslo, Norway.